SAGE Therapeutics (SAGE) Upgraded at BidaskClub

SAGE Therapeutics (NASDAQ:SAGE) was upgraded by stock analysts at BidaskClub from a “sell” rating to a “hold” rating in a report released on Tuesday, February 5th.

A number of other analysts also recently issued reports on SAGE. Canaccord Genuity set a $220.00 target price on shares of SAGE Therapeutics and gave the stock a “buy” rating in a research report on Thursday, November 1st. Leerink Swann began coverage on shares of SAGE Therapeutics in a research report on Monday, November 12th. They issued an “underperform” rating and a $80.00 price objective for the company. Oppenheimer set a $170.00 target price on SAGE Therapeutics and gave the company a “buy” rating in a research note on Tuesday, November 20th. Cowen reiterated a “buy” rating and set a $207.00 target price on shares of SAGE Therapeutics in a research note on Thursday, November 1st. Finally, JPMorgan Chase & Co. set a $205.00 target price on SAGE Therapeutics and gave the company a “buy” rating in a research note on Tuesday, November 6th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and twelve have issued a buy rating to the company. SAGE Therapeutics has a consensus rating of “Buy” and a consensus price target of $201.45.

Shares of NASDAQ:SAGE traded down $0.24 during midday trading on Tuesday, reaching $159.01. The company’s stock had a trading volume of 428,359 shares, compared to its average volume of 480,619. SAGE Therapeutics has a twelve month low of $79.88 and a twelve month high of $188.82. The firm has a market capitalization of $7.25 billion, a P/E ratio of -19.68 and a beta of 2.93.

SAGE Therapeutics (NASDAQ:SAGE) last announced its quarterly earnings results on Tuesday, February 19th. The biopharmaceutical company reported ($3.38) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($2.89) by ($0.49). The company had revenue of $0.27 million for the quarter. During the same quarter in the prior year, the firm earned ($1.75) EPS. Equities research analysts forecast that SAGE Therapeutics will post -12.51 EPS for the current fiscal year.

In related news, CFO Kimi Iguchi sold 25,563 shares of the firm’s stock in a transaction on Friday, March 1st. The stock was sold at an average price of $156.93, for a total transaction of $4,011,601.59. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director James M. Frates sold 7,500 shares of the stock in a transaction on Wednesday, January 23rd. The stock was sold at an average price of $134.81, for a total value of $1,011,075.00. Following the completion of the sale, the director now directly owns 11,735 shares in the company, valued at $1,581,995.35. The disclosure for this sale can be found here. Insiders have sold 109,015 shares of company stock worth $17,000,466 over the last 90 days. 5.10% of the stock is currently owned by company insiders.

Hedge funds and other institutional investors have recently modified their holdings of the business. Russell Investments Group Ltd. increased its position in SAGE Therapeutics by 57.8% in the third quarter. Russell Investments Group Ltd. now owns 193,730 shares of the biopharmaceutical company’s stock worth $27,286,000 after buying an additional 70,962 shares during the period. FMR LLC increased its holdings in shares of SAGE Therapeutics by 1.6% during the second quarter. FMR LLC now owns 6,977,378 shares of the biopharmaceutical company’s stock valued at $1,092,169,000 after purchasing an additional 110,687 shares during the period. BlackRock Inc. increased its holdings in shares of SAGE Therapeutics by 0.9% during the third quarter. BlackRock Inc. now owns 2,816,410 shares of the biopharmaceutical company’s stock valued at $397,818,000 after purchasing an additional 23,862 shares during the period. Mackenzie Financial Corp increased its holdings in shares of SAGE Therapeutics by 9.5% during the third quarter. Mackenzie Financial Corp now owns 17,175 shares of the biopharmaceutical company’s stock valued at $2,426,000 after purchasing an additional 1,486 shares during the period. Finally, Strs Ohio increased its holdings in shares of SAGE Therapeutics by 571.4% during the third quarter. Strs Ohio now owns 142,417 shares of the biopharmaceutical company’s stock valued at $20,116,000 after purchasing an additional 121,206 shares during the period.

SAGE Therapeutics Company Profile

Sage Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system disorders. Its lead product candidate comprises brexanolone, a proprietary intravenous formulation of allopregnanolone that has completed III clinical trials for the treatment of post-partum depression (PPD).

Featured Article: Market Capitalization, Large-Caps, Mid-Caps, Small-Caps

Analyst Recommendations for SAGE Therapeutics (NASDAQ:SAGE)

Receive News & Ratings for SAGE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAGE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.